Corcept Therapeutics Incorporated· CORT
🇺🇸 US · LargeSP600NASDAQ
- Price
- $111.62
- Day
- -1.05%
- Mkt Cap
- $12.07B
- 52W Range
- $28.66 – $126.38
- Volume
- 601.5K
- Beta
- 0.46
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT
Bank of America Corp DE raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 33.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,736 shares of the biotechnology company's stock after acquiring an additional 28,078 shares during the period. Bank
Bank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORT
Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 565,666 shares of the biotechnology company's stock, valued at approximately $49,185,000. Bank of New York Mellon Corp owned approximately
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT
BlackRock Inc. bought a new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,432,023 shares of the biotechnology company's stock, valued at approximately $1,080,964,000. BlackRock Inc. owned about 11.50% of
Like The Knick's, Corcept Rebounded And Is Crushing It
Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.